Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir

Journal of Virology

Volumn 75, Issue 2, 2001, Pages 589-594

  Cote H C F ^a   Brumme, Z L ^a   Harrigan, P R ^a  

^a ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; MUTANT PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

AMINO ACID SUBSTITUTION; ARTICLE; ENZYME ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PREVALENCE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR;

EID: 0035163687     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.2.589-594.2001     Document Type: Article

References (24)

1. Resistance to human immunodeficiency virus type 1 protease inhibitors
2. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
3. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity; and drug sensitivity
4. The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity
5. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
6. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
7. HIV-1 protease specificity of peptide cleavage is sufficient for processing of Gag and Pol polyproteins
8. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
9. A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease
10. Cleavage of recombinant and cell derived human immunodeficiency virus 1 (HIV-1) Nef protein by HIV-1 protease
11. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
12. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society - USA Panel
13. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
14. Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease
15. Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism
16. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
17. The specificity of the HIV-1 protease
18. Human immunodeficiency virus reverse transcriptase and protease sequence database
19. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase
20. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease
21. The Gag precursor contains a specific HIV-I protease cleavage site between the NC (p7) and p1 proteins
22. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
23. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites